Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02922764
Title A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rgenix, Inc.
Indications

lymphoma

ovary epithelial cancer

fallopian tube carcinoma

Advanced Solid Tumor

lung small cell carcinoma

peritoneal carcinoma

lung non-small cell carcinoma

Therapies

RGX-104

Ipilimumab + RGX-104

Nivolumab + RGX-104

Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.